drugset / Trial / NCT06116045

Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder

NCT06116045

Phase 2 Recruiting 30 enrolled Biozeus Biopharmaceutical S.A.
RandomizedCrossoverQuadruple-blindTreatment

Summary

To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.

Timeline

Start
2024-10-01
Primary completion
2025-02-01
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BZ371A Unknown 2.5 mg Topical
Subject BZ371A Unknown 5 mg Topical
Subject BZ371A Unknown 7.5 mg Topical

Indications